

Abstract Presentations of Rutgers Cancer Institute of New Jersey/RWJBarnabas Health Physicians at the 64th American Society of Hematology Annual Meeting & Exposition

(All times noted are Central Standard Time – Meeting is in New Orleans, LA)**

Saturday, December 10, 2022

12:45 pm

Double Hit/Double Expressor Lymphomas: A Multicenter Analysis of Survival Outcomes with CD19-Directed CAR T-Cell Therapy

Author: [Andrew M. Evens, DO, MBA, MSc](#)

Program: [Oral](#)

4:00 pm

Development and Validation of the advanced Stage Hodgkin Lymphoma (HL) International Prognostication Index (A-HIPI): A Report from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium

Senior Author: [Andrew M. Evens, DO, MBA, MSc](#)

Program: [Oral](#)

5:30-7:30 pm

Prognostic Importance of Cytogenetic Subgroups in Relapse Risk Stratification in Children and Young Adults with First Relapsed B-ALL: A Children's Oncology Group Study AALL1331

Lead Author: [Teena Bhatla, MD](#)

Program: [Poster](#)

Outpatient Vyxeos Induction without Planned Admission for Select Patients with Secondary Acute Myeloid Leukemia (sAML): A Multicenter Analysis of Safety and Healthcare Resource Utilization

Author: [Neil D. Palmisiano, MD, MS](#)

Program: [Poster](#)

Mutations of ATM Confer a Risk of Inferior Survival in Patients with TP53-wild Type Mantle Cell Lymphoma

Author: [Andrew M. Evens, DO, MBA, MSc](#)

Program: [Poster](#)

High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Central Nervous System (CNS) Involvement, Prophylaxis, and Recurrence Risk in a Multi-Institutional Series

Author: [Andrew M. Evens, DO, MBA, MSc](#)

Program: [Poster](#)

Subcutaneous Mosunetuzumab Is Active with a Manageable Safety Profile in Patients (pts) with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphomas (B-NHLs): Updated Results from a Phase I/II Study

Author: [Matthew J. Matasar, MD, MS](#)

Program: [Poster](#)

Population Pharmacokinetics and Exposure–Response Analyses from Phase I-III Studies Support Copanlisib Dose Selection in Relapsed Indolent Non-Hodgkin Lymphoma

Author: [Matthew J. Matasar, MD, MS](#)

Program: [Poster](#)

Sunday, December 11, 2022

10:15 am

Polatuzumab Vedotin Combined with R-ICE (PolaR-ICE) As Second-Line Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Senior Author: [Matthew J. Matasar, MD, MS](#)

Program: [Oral](#)

12:15 pm

Risk Profiling of Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) By Measuring Circulating Tumor DNA (ctDNA): Results from the POLARIX Study

Author: [Matthew J. Matasar, MD, MS](#)

Program: [Oral](#)

5:15 pm

Mosunetuzumab Monotherapy Demonstrates Durable Efficacy with a Manageable Safety Profile in Patients with Relapsed/Refractory Follicular Lymphoma Who Received ≥ 2 Prior Therapies: Updated Results from a Pivotal Phase II Study

Author: [Matthew J. Matasar, MD, MS](#)

Program: [Oral](#)

5:30 pm

Predictors of Long-Term Outcome in TP53-Mutated Acute Myeloid Leukemia Patients Receiving Allogeneic Stem Cell Transplant after First- or Second-Line Therapy: Results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Author: [Neil D. Palmisiano, MD, MS](#)

Program: [Oral](#)

6:00-8:00 pm

COVID-19 Infection in Children with Down Syndrome and Hematologic Malignancies

Author: [Archana Sharma, DO](#)

Program: [Poster](#)

Clinical Outcomes of Patients with TP53-Mutated AML after First Relapse or with Primary Refractory Disease: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Author: [Neil D. Palmisiano, MD, MS](#)

Program: [Poster](#)

FLIPI-3: A New PET-Based Prognostic Index for Follicular Lymphoma Based on Results from a Validation Study with the ECOG-ACRIN E2408 Cohort

Author: [Andrew M. Evens, DO, MBA, MSc](#)

Program: [Poster](#)

Favorable Overall Survival Following First and Second Relapse of MCL with Availability of Novel Therapies: Results from the Lion Prospective Observational Registry

Author: [Andrew M. Evens, DO, MBA, MSc](#)

Program: [Poster](#)

Identification of Genetic Subtypes in Follicular Lymphoma

Author: [Andrew M. Evens, DO, MBA, MSc](#)

Program: [Poster](#)

Pharmacodynamics and Biomarker Correlates of Imvotamab (IGM-2323), the First-in-Class CD20xCD3 Bispecific IgM Antibody with Dual Mechanisms of Action, in Patients with Advanced B Cell Malignancies

Author: [Matthew J. Matasar, MD, MS](#)

Program: [Poster](#)

Pooled Safety Analysis from Phase I–III Studies for Patients with Hematological Malignancies Treated with the PI3K Inhibitor Copanlisib

Author: [Matthew J. Matasar, MD, MS](#)

Program: [Poster](#)

Monday, December 12, 2022

11:15 am

Brentuximab Vedotin Combined with Chemotherapy in Newly Diagnosed, Early-Stage, Unfavorable-Risk Hodgkin Lymphoma: Extended Follow-up with Evaluation of Baseline Metabolic Tumor Volume and PET2

Author: [Matthew J. Matasar, MD, MS](#)

Program: [Oral](#)

11:45 am

Randomized Phase II Study to Assess the Role of Nivolumab As Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients after Chemotherapy (NCI9706 protocol; REMAIN Trial)

Author: [Neil D. Palmisiano, MD, MS](#)

Program: [Oral](#)

5:15 pm

Consensus Cachexia Criteria Are Independently Linked to Progression Free and Overall Survival in Multi-Site Analysis of Patients with Aggressive B-Cell Lymphomas Treated with CAR T-Cell Therapy

Author: [Andrew M. Evens, DO, MBA, MSc](#)

Program: [Oral](#)

6:00-8:00 pm

Leg Ulcer Prevalence and Outcomes in a Real-World, Multicenter, Retrospective Study of Patients Treated with Voxelotor

Authors: [Richard A. Drachtman, MD](#), [Archana Sharma, DO](#)

Program: [Poster](#)

Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human Study

Author: [Mansi R. Shah, MD](#)

Program: [Poster](#)

Impact of Race and Social Determinants of Health on Outcomes in Patients with Aggressive B-Cell Lymphomas Treated with Chimeric Antigen Receptor T-Cell (CART) Therapy

Author: [Andrew M. Evens, DO, MBA, MSc](#)

Program: [Poster](#)

Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Final Results of a Phase Ib/II Randomized Study and Single-Arm Extension (Ext) Study

Senior Author: [Matthew J. Matasar, MD, MS](#)

Program: [Poster](#)

Immune Signature of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma

Author: [Matthew J. Matasar, MD, MS](#)

Program: [Poster](#)

Adult T-Cell Leukemia/Lymphoma Diagnosed in North American Is Characterized By a Requirement for BCL6 and a Cell Cycle Program Associated with DNA Replication Stress

Author: [Advaita Madireddy, PhD](#)

Program: [Poster](#)